LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.58 -1.38

Buy Sell

Overview

Share price change

24h

Current

Min

3.33

Max

3.63

Key metrics
By Trading Economics
Income	-511K -28M
Sales	-13M 2.6M
EPS	-0.47
Profit margin	-1,077.401
Employees	141
EBITDA	-455K -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+302.66% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	15M 249M
Previous open	4.96
Previous close	3.58

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 maj 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Agilysys, XP

18 maj 2026, 18:44 UTC

Major Market Movers

Claritev Shares Recover After Comments About DOJ

18 maj 2026, 23:55 UTC

Earnings

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 maj 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 maj 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 maj 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 maj 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

18 maj 2026, 20:25 UTC

Earnings

Correct: XP 1Q Total Client Assets BRL1.53T

18 maj 2026, 20:23 UTC

Earnings

XP 1Q Total Client Assets BRL1.53B

18 maj 2026, 20:19 UTC

Earnings

XP 1Q Adj EPS BRL2.49 >XP

18 maj 2026, 20:19 UTC

Earnings

XP 1Q Rev BRL4.73B >XP

18 maj 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 maj 2026, 19:00 UTC

Earnings

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 maj 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 maj 2026, 18:17 UTC

Market Talk

Acquisitions, Mergers, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 maj 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 maj 2026, 16:57 UTC

Acquisitions, Mergers, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 maj 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 maj 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 maj 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 maj 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 maj 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 maj 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 maj 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Vinci Buys Canada's Modern Group of Companies

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

302.66% upside

12 Months Forecast

Average 15.14 USD 302.66%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.